Sarepta Therapeutics, Inc. (SRPT)
NASDAQ: SRPT · IEX Real-Time Price · USD
154.20
-2.55 (-1.63%)
At close: Jul 2, 2024, 4:00 PM
156.00
+1.80 (1.17%)
After-hours: Jul 2, 2024, 4:57 PM EDT
Sarepta Therapeutics Employees
Sarepta Therapeutics had 1,314 employees as of December 31, 2023. The number of employees increased by 152 or 13.08% compared to the previous year.
Employees
1,314
Change (1Y)
152
Growth (1Y)
13.08%
Revenue / Employee
$1,067,960
Profits / Employee
$12,859
Market Cap
14.58B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1,314 | 152 | 13.08% |
Dec 31, 2022 | 1,162 | 322 | 38.33% |
Dec 31, 2021 | 840 | -26 | -3.00% |
Dec 31, 2020 | 866 | 123 | 16.55% |
Dec 31, 2019 | 743 | 244 | 48.90% |
Dec 31, 2018 | 499 | 244 | 95.69% |
Dec 31, 2017 | 255 | 58 | 29.44% |
Dec 31, 2016 | 197 | -73 | -27.04% |
Dec 31, 2015 | 270 | 66 | 32.35% |
Dec 31, 2014 | 204 | 58 | 39.73% |
Dec 31, 2013 | 146 | 43 | 41.75% |
Dec 31, 2012 | 103 | 5 | 5.10% |
Dec 31, 2011 | 98 | 0 | - |
Dec 31, 2010 | 98 | 35 | 55.56% |
Dec 31, 2009 | 63 | -20 | -24.10% |
Dec 31, 2008 | 83 | -42 | -33.60% |
Dec 31, 2007 | 125 | 8 | 6.84% |
Dec 31, 2006 | 117 | -6 | -4.88% |
Dec 31, 2005 | 123 | 11 | 9.82% |
Dec 31, 2004 | 112 | 6 | 5.66% |
Dec 31, 2003 | 106 | 17 | 19.10% |
Dec 31, 2002 | 89 | 4 | 4.71% |
Dec 31, 2001 | 85 | 14 | 19.72% |
Dec 31, 2000 | 71 | 15 | 26.79% |
Dec 31, 1999 | 56 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Quest Diagnostics | 48,000 |
BeiGene | 10,600 |
Waters | 7,900 |
BioMarin Pharmaceutical | 3,401 |
Natera | 3,293 |
Insulet | 3,000 |
Incyte | 2,524 |
Genmab | 2,204 |
SRPT News
- 4 days ago - Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 7 days ago - Will Elevidys Approval Make Sarepta Stock An Acquisition Target? - Forbes
- 11 days ago - Sarepta's Expanded Approval Unlikely To Influence Novo Holdings' Acquisition of Catalent, But Provides Investor Protection Amid Uncertainty - Benzinga
- 11 days ago - Wall Street Beats to Host Conference Call with Sarepta CEO on Ground-Breaking Expanded Label Approval - Business Wire
- 11 days ago - Sarepta's Expanded FDA Approval For Elevidys Potentially Shaping Future FDA Reviews, Analyst Says - Benzinga
- 11 days ago - Sarepta Therapeutics Soars on Expanded Approval for Its Muscular Dystrophy Drug - Investopedia
- 11 days ago - Sarepta Therapeutics' stock soars 38% after FDA expands use of its Duchenne muscular-dystrophy drug - Market Watch
- 11 days ago - Sarepta Stock Surges on Expanded Approval for Elevidys. What Wall Street Thinks. - Barrons